Belgian physician, himself living with myasthenia gravis. More than 30 years of entrepreneurial experience in MedTech and biotech.
Stéphane Huberty is the founder and CEO of CuraVac. He also founded and leads IDEAS in Belgium, specialised in the CAD/CAM production of custom orthopaedic and standard footwear, for which he received the Young Entrepreneur of the Year award in 1993. A medical doctor and graduate of the Université catholique de Louvain (UCL), he specialised during his studies in the use of computers in medicine and worked as a research fellow at UCLA. He studied Professor Blalock's research for personal reasons, being himself affected by myasthenia gravis.
Dr. Jean-Paul Prieels
Director
Ph.D., former SVP R&D at GSK Vaccines; contributed to bringing several vaccines to market.
A doctor of science, Jean-Paul Prieels was Senior Vice President of Research and Development at GlaxoSmithKline Biologicals (now GSK Vaccines) until January 2011. He joined in 1987 as Associate Director for R&D project evaluation, before leading global vaccine development activities in Rixensart. His career spans from basic research to process and product development; he contributed to bringing several vaccines to market (rotavirus, human papillomavirus, pneumococcal conjugates). A director of Vaximm AG and, since 2007, a member of the scientific board of the Singapore Bioprocessing Technology Institute, he chairs the board of Immune Health and sat on the board of Henogen (2000-2008).
Director, Operations Director
25+ years in pharmaceutical biotech (GSK Vaccines, Novasep, CEPI). Chemical engineer and biotechnologist.
Nicolas Havelange is a pharmaceutical biotechnology expert with 25 years of experience in biopharmaceutical process development and manufacturing (mammalian and microbial systems, mRNA, synthetic peptides). He advises funders, foundations and biotech/pharma companies on process development, cGMP manufacturing, CMO and project management, and business development. As a CMC consultant for CEPI, he took part in several mRNA Covid-19 vaccine projects. After various roles at SmithKline Beecham Biologicals, he helped launch Henogen, Artelis/ATMI, the European Vaccine Initiative and other biotechs. He is a chemical engineer (ULB Polytechnic School) and holds a master's in molecular biology and biotechnology (ULB).
Leone Flynn
Administrative Director
Administrative Director since CuraVac's earliest days; executive master's in marketing (Solvay).
Leone Flynn has been CuraVac's Chief Administrative Officer since its inception in 2002. She is also the founder and director of PodoProductions, a custom foot-orthotics milling service. She holds a degree in International Business from University College Dublin and an Executive Master's in marketing from the Solvay Business School in Brussels.
15 years in corporate finance. Bioengineer (UCLouvain) and Solvay; formerly PwC.
Matthieu André brings 15 years of corporate-finance experience, with a strong focus on financial planning and analysis, business controlling, and treasury and working-capital management. Before industry, he worked in treasury risk-management consulting at PwC. He holds a master's in chemistry and bio-industries from the Université catholique de Louvain and an Advanced Master in Financial Markets from the Solvay Brussels School of Economics & Management.
Olivier André
Business Development
Consultant in development, licensing and lean management for biotechs. Bioengineer.
Nathalie Thyssen
Regulatory affairs
Industrial pharmacist; 20 years in drug development and registration (vaccines, ATMPs).
Samuel Osumba
Project Manager
20+ years in pharma; joined CuraVac in 2020 for the MYASTERIX program (formerly Pfizer, Artelis).
With over 20 years of experience in the pharmaceutical industry, Samuel Osumba started out in the quality-control laboratories of Solvay, Pfizer and Laborelec. In 2006 he joined the vaccine and cell-therapy start-up Artelis and contributed to the design of single-use bioreactors and mixers, for which he is co-owner of a patent filed in 2007. He joined CuraVac in 2020 as project manager for the Myasterix programme.
Dr. Olivier Stevens, DVM
Veterinary medicine
Veterinarian specialized in small-animal family practice. He has followed CuraVac's development since its inception.
